The XXVI promotion of the UniversityMaster's Degree in research and development +I of Medicines (MIDI) has closed with 22 new graduates in one of the most prestigious postgraduate courses in its field, issue one of the ranking of masters of the newspaper El Mundo since its inception.

Dr. Julen Oyarzabal, director of Translational Science of the research center Applied Medicine of the University of Navarra (CIMA), was in charge of giving the closing lecture , entitled "Campus Biomedical: core topic in the finding of drugs". In it, the expert recalled that investment in research and development+I for the development of new drugs has tripled in the last twenty years: "At the same time, the issue of drugs approved annually remains constant, which means that work is being done to improve processes".

"In fact," he added, "the association of biopharmaceutical companies in America(PhRMA) urges companies to position themselves in a dynamic research and development+i ecosystem. That is, they should take advantage of the added value of being in a continuous and direct contact with the clinical research (patients), the biomedical research centers and the academic environment (the university)."

In this sense, he recalled that the synergies created in a biomedical campus -where the clinical research of the CUN, the biomedical of CIMA, all in an academic environment (University) and with biopharmaceutical companies are combined- "is core topic for the development of new drugs that cover medical needs, such as the treatment of Alzheimer's disease". In this ailment, he added, "99.6% of the potential drugs developed in the last 15 years have failed," which gives an idea of the potential of research in this field.